What the research found

A survey of over 5,000 people with hypothyroidism revealed that brain fog—described as a cluster of low energy, forgetfulness, sleepiness, and difficulty concentrating—affects the majority regularly rather than occasionally. The respondents were predominantly female (>95%), and nearly half had autoimmune thyroid disease, though many were unaware of their condition's underlying cause.

The proposed mechanism centres on incomplete brain penetration of levothyroxine therapy. Despite TSH normalisation, thyroid hormone activity in neural tissue may remain suboptimal. This creates a "cognitive reserve deficit"—when mental demands spike (multitasking, complex problem-solving, memory work), available cognitive capacity falls short, triggering the fog symptoms. Mood symptoms like anxiety and depression accompanied the cognitive complaints, though less consistently.

When asked what helped, participants most commonly cited rest and sleep (>50%), with smaller groups reporting benefit from exercise (~10%) or alternative thyroid treatments such as liothyronine or desiccated thyroid extract (~12%). The authors note no robust evidence currently favours these alternatives over standard levothyroxine monotherapy, though outcomes remain broadly similar across approaches.

Why it matters for you

If you're tracking thyroid biomarkers on MyKine, a normal TSH doesn't guarantee you'll feel cognitively sharp—particularly during periods of high mental load. The "cognitive reserve" framework suggests you might benefit from deliberate rest scheduling and sleep prioritisation, especially when juggling multiple work or training demands. This isn't laziness; it's resource allocation.

For those experimenting with combination T4/T3 therapy or other formulations, the survey hints that some people report subjective improvement, even without large-scale evidence backing superiority. This highlights a gap: your individual response may differ from population averages. If you're considering protocol changes, tracking specific cognitive markers (reaction time, decision-making speed, focus duration) alongside your TSH and free T4/T3 levels could reveal whether a switch genuinely helps you.

Sleep and rest emerged as the most commonly reported interventions. Given how thyroid hormone influences mitochondrial function and metabolic rate, poor recovery may amplify any underlying cognitive deficit. If you're training hard or managing stress, thyroid-optimised individuals may need to be more disciplined about sleep, not less.

Caveats

• Observational and self-reported: Survey respondents described their own experiences; no control group or objective cognitive testing is detailed here.
• Demographic skew: >95% female respondents; findings may not generalise equally to men.
• No mechanistic proof: The cognitive reserve hypothesis is plausible but remains unproven; causality between partial brain T4/T3 replacement and fog is inferred, not demonstrated.
• Alternative therapy claims lack RCT support: The 12% reporting benefit from non-levothyroxine treatments is anecdotal; no evidence yet shows superiority.
• No dosing or titration data: The study doesn't explore whether optimising levothyroxine dose (rather than switching agents) resolves symptoms in some patients.